Goodman Advisory Group LLC Acquires Shares of 8,997 IQVIA Holdings Inc. $IQV

Goodman Advisory Group LLC bought a new position in IQVIA Holdings Inc. (NYSE:IQV) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 8,997 shares of the medical research company’s stock, valued at approximately $1,534,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Ameliora Wealth Management Ltd. acquired a new stake in IQVIA in the fourth quarter valued at about $25,000. International Assets Investment Management LLC acquired a new position in IQVIA during the 4th quarter worth approximately $27,000. Gilpin Wealth Management LLC purchased a new position in shares of IQVIA during the 4th quarter worth approximately $27,000. CrossGen Wealth LLC acquired a new stake in shares of IQVIA in the 4th quarter valued at approximately $28,000. Finally, Measured Wealth Private Client Group LLC purchased a new stake in shares of IQVIA in the third quarter valued at approximately $30,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IQV has been the subject of several research analyst reports. Royal Bank Of Canada assumed coverage on IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective for the company. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and boosted their target price for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Weiss Ratings cut shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. HSBC set a $210.00 price objective on shares of IQVIA in a research note on Wednesday, June 3rd. Finally, Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $222.56.

IQVIA Stock Performance

IQVIA stock opened at $191.12 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $247.04. The company has a market capitalization of $31.90 billion, a price-to-earnings ratio of 23.68, a PEG ratio of 1.64 and a beta of 1.21. The stock has a fifty day moving average of $174.43 and a two-hundred day moving average of $190.07. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the business earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, analysts anticipate that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA declared that its board has authorized a share repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.